A61K 31/537
Spiro-condensed or forming part of bridged ring systems
Official title: spiro-condensed or forming part of bridged ring systems
A61K31/537 (Spiro-condensed or forming part of bridged ring systems) appears on 211 US grants and 432 published applications in this corpus.
Search patents in A61K- Granted patents
- 211
- Published applications
- 432
- Assignees
- 192
- Inventors
- 989
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 3 | 8 |
| 2003 | 3 | 14 |
| 2004 | 1 | 17 |
| 2005 | 4 | 11 |
| 2006 | 5 | 27 |
| 2007 | 3 | 7 |
| 2008 | 4 | 10 |
| 2009 | 2 | 9 |
| 2010 | 10 | 11 |
| 2011 | 5 | 11 |
| 2012 | 5 | 8 |
| 2013 | 11 | 14 |
| 2014 | 9 | 22 |
| 2015 | 13 | 20 |
| 2016 | 12 | 33 |
| 2017 | 24 | 28 |
| 2018 | 16 | 21 |
| 2019 | 12 | 22 |
| 2020 | 17 | 23 |
| 2021 | 8 | 13 |
| 2022 | 13 | 27 |
| 2023 | 6 | 17 |
| 2024 | 11 | 25 |
| 2025 | 5 | 22 |
| 2026 | 9 | 12 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treating residual breast cancer with trastuzumab emtansine22 Sep 2026US 12,740,962 B2Genentech, Inc.
- Anti-CLDN18.2 antibody, drug conjugate, and preparation method therefor and use thereof22 Sep 2026US 12,741,032 B2Cspc Megalith Biopharmaceutical Co., Ltd.
- Maytansinoid derivatives, conjugates thereof, and methods of use28 Jul 2026US 12,691,182 B2Regeneron Pharmaceuticals, Inc.
- Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition16 Jun 2026US 12,653,809 B2Nurix Therapeutics, Inc.
- Formulations and dosages for administering a compound that inhibits MCL1 protein12 May 2026US 12,622,918 B2Amgen Inc.
- Raf-mek protein complex modulators and methods of use thereof1 Oct 2026US 2026/0297105 A1Gandeeva Therapeutics, Inc.
- Inhibitors of parg24 Sep 2026US 2026/0285875 A1858 Therapeutics, Inc.
- Pharmaceutical composition and method for treatment of human immunodeficiency virus infections27 Aug 2026US 2026/0248834 A1Brii Biosciences, Inc.
- Treatment Of Nicotinamide Phosphoribosyltransferase (NAMPT) Related Diseases6 Aug 2026US 2026/0224657 A1Institute for Cancer Research D/B/A the Research Institute of Fox Chase Cancer
- Benzopyrone compounds as well as preparation method therefor and use thereof16 Jul 2026US 2026/0200885 A1Chengdu Di’ao Jiuhong Pharmaceutical Factory
Most cited
By later US patents
- Inhibitors of histone deacetylase67US 6,897,220 B2MethylGene Inc. · 2005
- Methods of treating cytokine mediated diseases53US 7,211,575 B2Boehringer Ingelheim Pharmaceuticals, Inc. · 2007
- Folate receptor 1 antibodies and immunoconjugates and uses thereof49US 8,557,966 B2ImmunoGen, Inc. · 2013
- Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections49US 9,216,996 B2Gilead Sciences, Inc. · 2015
- Anti-CD79B antibodies and immunoconjugates and methods of use38US 8,545,850 B2Genentech, Inc. · 2013